Follow
Rachel Kerr (nee Midgley)
Rachel Kerr (nee Midgley)
Verified email at oncology.ox.ac.uk
Title
Cited by
Cited by
Year
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
N Bhala, J Emberson, A Merhi, S Abramson, N Arber, JA Baron, ...
Lancet (London, England) 382 (9894), 769-779, 2013
15992013
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
LYW Lee, JB Cazier, V Angelis, R Arnold, V Bisht, NA Campton, ...
The Lancet 395 (10241), 1919-1926, 2020
11942020
Genetic prognostic and predictive markers in colorectal cancer
A Walther, E Johnstone, C Swanton, R Midgley, I Tomlinson, D Kerr
Nature Reviews Cancer 9 (7), 489-499, 2009
9632009
Duration of adjuvant chemotherapy for stage III colon cancer
A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ...
New England Journal of Medicine 378 (13), 1177-1188, 2018
8982018
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
DH Palmer, RS Midgley, N Mirza, EE Torr, F Ahmed, JC Steele, ...
Hepatology 49 (1), 124-132, 2009
6382009
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ...
The Lancet Oncology 21 (10), 1309-1316, 2020
6092020
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised …
C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ...
The lancet oncology 20 (6), 849-861, 2019
4282019
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26. 2, 12q13. 13 and 20q13. 33
RS Houlston, J Cheadle, SE Dobbins, A Tenesa, AM Jones, K Howarth, ...
Nature genetics 42 (11), 973-977, 2010
4222010
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
OJ Skrede, S De Raedt, A Kleppe, TS Hveem, K Liestøl, J Maddison, ...
The Lancet 395 (10221), 350-360, 2020
4202020
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
SJ Dutton, DR Ferry, JM Blazeby, H Abbas, A Dahle-Smith, W Mansoor, ...
The lancet oncology 15 (8), 894-904, 2014
3172014
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial
A Huijbers, R Tollenaar, GW v Pelt, ECM Zeestraten, S Dutton, ...
Annals of oncology 24 (1), 179-185, 2013
2992013
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ...
The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016
2782016
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk
MG Dunlop, SE Dobbins, SM Farrington, AM Jones, C Palles, N Whiffin, ...
Nature genetics 44 (7), 770-776, 2012
2782012
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis
D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ...
Journal of Clinical Oncology 32 (10), 1031, 2014
2582014
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
J Tie, L Lipton, J Desai, P Gibbs, RN Jorissen, M Christie, KJ Drummond, ...
Clinical Cancer Research 17 (5), 1122-1130, 2011
2582011
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer
E Domingo, DN Church, O Sieber, R Ramamoorthy, Y Yanagisawa, ...
J clin Oncol 31 (34), 4297-4305, 2013
2382013
Association analyses identify 31 new risk loci for colorectal cancer susceptibility
PJ Law, M Timofeeva, C Fernandez-Rozadilla, P Broderick, J Studd, ...
Nature communications 10 (1), 2154, 2019
2012019
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
TJ Iveson, RS Kerr, MP Saunders, J Cassidy, NH Hollander, J Tabernero, ...
The Lancet Oncology 19 (4), 562-578, 2018
1802018
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
RS Kerr, S Love, E Segelov, E Johnstone, B Falcon, P Hewett, A Weaver, ...
The Lancet Oncology 17 (11), 1543-1557, 2016
1652016
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer
DJ Kerr, JA Dunn, MJ Langman, JL Smith, RSJ Midgley, A Stanley, ...
New England Journal of Medicine 357 (4), 360-369, 2007
1632007
The system can't perform the operation now. Try again later.
Articles 1–20